Spero Therapeutics CEO sells $63,352 in company stock

Spero Therapeutics reported a strong Q4 beat, with adjusted EPS of $0.53 versus -$0.20 expected and revenue of $41.3 million versus $26 million consensus, up 175% year over year. The company also posted full-year 2025 net income of $8.6 million versus a $68.6 million loss in 2024, highlighting a sharp turnaround driven by collaboration revenue from GSK and Pfizer. Separately, CEO/CFO/CB0 Esther Rajavelu sold 25,240 shares in an automatic sell-to-cover transaction, leaving her with 986,851 shares.

Analysis

SPRO is becoming a classic “fundamentals outrun optics” setup: the headline purchase-sounding insider event is non-economic, while the real signal is that the business has crossed into a partnership-driven cash generation phase. That matters because once biotech transitions from pure burn story to royalty/collaboration monetization, valuation typically rerates less on binary clinical milestones and more on contract durability and renewal leverage; the market often underestimates how sticky that revenue can be once counterparty integration costs are sunk.

The second-order effect is that GSK and PFE are effectively underwriting SPRO’s upside optionality. For the large partners, small-dollar collaboration expense is immaterial, but for SPRO the same dollars can swing the company from capital scarcity to self-funding; that asymmetry can keep the stock bid even if underlying core product sales are not yet meaningful. The flip side is concentration risk: if one partner rephases development or changes commercial priorities, the equity can de-rate violently because the current multiple is likely embedding a relatively narrow revenue base.

The market is probably still pricing SPRO like a “recovering microcap biotech” rather than a cash-generative platform with multiple shots on goal. The contrarian read is that this could be over-owned by momentum traders after the 338% run, but still under-owned by fundamental healthcare managers who need proof of recurring, non-dilutive revenue before they will re-rate it. That creates a two-speed tape: near-term volatility from profit-taking, medium-term support if the next quarter confirms that profitability is not purely timing-driven.

Near term, the main risk is that collaboration revenue is lumpy and can reverse expectations quickly if quarterly timing normalizes. Over the next 3-6 months, the stock’s biggest catalyst is not another beat, but evidence that gross profit and operating cash flow remain positive absent one-time partnership timing benefits; if that happens, the stock can still rerate despite the recent move. If it doesn’t, the prior rally becomes vulnerable to a sharp multiple compression even without operational deterioration.

Key Decisions for Investors

• Long SPRO on pullbacks over the next 2-4 weeks, but size modestly; target a continuation trade into the next print with asymmetric upside if management confirms repeatable partnership revenue and positive cash generation.
• Use call spreads rather than stock for SPRO into the next 1-2 quarters: buy 3-6 month calls and finance with higher strikes to express upside while limiting drawdown risk after a 338% run.
• If you are already long SPRO, trim 25-35% into strength and retain a core position; the stock is likely to be driven by sentiment and revenue timing more than by linear fundamentals in the near term.
• Pair trade: long SPRO / short a basket of lower-quality cash-burning microcap biotechs over 1-3 months to isolate the rerating from non-dilutive revenue versus broad sector beta.
• Add a risk trigger: if the next quarter shows any deceleration in collaboration revenue or margins normalize lower, exit quickly; the stock can give back a large portion of gains because the current valuation is likely momentum-supported.